CEL-SCI CORPORATION Increase (Decrease) in Employee Related Liabilities
CEL-SCI CORPORATION (CVM) reported Increase (Decrease) in Employee Related Liabilities of -$26.18 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-14
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $33.04K, a 89.41% decline year-over-year.
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$202.78K, a 167.76% decline year-over-year.
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $143.56K, a 26.31% decline year-over-year.
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2025-06-30 was $312.13K.
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for fiscal 2024 was -$193.94K, a 326.15% decline from fiscal 2023.
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for fiscal 2023 was $85.76K, a 58.27% decline from fiscal 2022.
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for fiscal 2022 was $205.50K.
- CEL-SCI CORPORATION increase (decrease) in employee related liabilities for fiscal 2021 was -$182.03K.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$169.74K derived: sum of 2 quarters · filed 2026-08-14 | -$26.18K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$202.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | -$59.23K 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $143.56K 10-Q · filed 2026-02-17 | |||
| 2025-06-30 | $312.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $611.42K derived: sum of 2 quarters · filed 2026-08-14 | $806.21K 10-Q · filed 2026-08-14 | $473.03K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $299.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $494.08K 10-Q · filed 2026-05-15 | $160.90K derived: sum of 3 quarters · filed 2026-05-15 | $105.78K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $194.80K 10-Q · filed 2026-02-17 | -$138.38K derived: sum of 2 quarters · filed 2026-02-17 | -$193.50K derived: sum of 3 quarters · filed 2026-02-17 | -$147.59K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$333.18K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-13 | -$388.30K derived: sum of 2 quarters · filed 2025-08-14 | -$342.39K derived: sum of 3 quarters · filed 2025-08-14 | -$193.94K 10-K · filed 2025-01-13 |
| 2024-06-30 | -$55.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-14 | -$9.21K derived: sum of 2 quarters · filed 2025-08-14 | $139.24K 10-Q · filed 2025-08-14 | $196.83K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $45.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $194.36K 10-Q · filed 2025-05-14 | $251.95K derived: sum of 3 quarters · filed 2025-05-14 | $242.32K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $148.45K 10-Q · filed 2025-02-14 | $206.04K derived: sum of 2 quarters · filed 2025-02-14 | $196.41K derived: sum of 3 quarters · filed 2025-02-14 | $155.12K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $57.58K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-13 | $47.96K derived: sum of 2 quarters · filed 2025-01-13 | $6.67K derived: sum of 3 quarters · filed 2025-01-13 | $85.76K 10-K · filed 2025-01-13 |
| 2023-06-30 | -$9.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-14 | -$50.91K derived: sum of 2 quarters · filed 2024-08-14 | $28.17K 10-Q · filed 2024-08-14 | $3.66K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$41.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-15 | $37.80K 10-Q · filed 2024-05-15 | $13.28K derived: sum of 3 quarters · filed 2024-05-15 | $21.18K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $79.09K 10-Q · filed 2024-02-14 | $54.57K derived: sum of 2 quarters · filed 2024-02-14 | $62.47K derived: sum of 3 quarters · filed 2024-02-14 | $75.54K derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-09-30 | -$24.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-21 | -$16.62K derived: sum of 2 quarters · filed 2023-12-21 | -$3.55K derived: sum of 3 quarters · filed 2023-12-21 | $205.50K 10-K · filed 2023-12-21 |
| 2022-06-30 | $7.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-10 | $20.97K derived: sum of 2 quarters · filed 2023-08-10 | $230.01K 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $13.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | $222.11K 10-Q · filed 2023-05-12 | ||
| 2021-12-31 | $209.05K 10-Q · filed 2023-02-14 | |||
| 2021-09-30 | -$182.03K 10-K · filed 2022-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |